打印本文 打印本文 关闭窗口 关闭窗口
Meta-analysis of randomized controlled trials comparing travoprost with latanoprost in the treatment of patients with open angle glaucoma or ocular hypertension
作者:程金伟  文章来源:第二军医大学附属长征医院  点击数241  更新时间:2012/9/13  文章录入:毛进  责任编辑:毛进
Purpose This meta-analysis was to evaluate the efficacy and tolerability of travoprost compared with latanoprost in patients with open angle glaucoma or ocular hypertension.
Methods Pertinent studies were identified through searches of the Cochrane Library, PubMed, EMBASE, and Chinese Biomedicine Database up toJune 1, 2008, using the terms travoprost, Travatan, latanoprost, and Xalatan. Internet searches of meeting abstracts and the manufacturers' databases were also performed. Randomized controlled trials comparing travoprost with latanoprost in patients with open angle glaucoma or ocular hypertension were selected. The main efficacy measures were the weighted mean difference (WMD) in the IOP reduction (IOPR). The main tolerability measure was the relative risk (RR) for adverse events.
Results Seventeen studies enrolling a total of 1491 patients were included in the meta-analysis. The WMDs in the diurnal mean IOPR comparing travoprost with latanoprost were1.47 mmHg (95% confidence interval, 0.33 to 2.62) at 2 weeks, 0.81 (-0.78 to 2.40) at 1 month, 0.71 (0.04 to 1.38) at 2 months, 0.01 (-0.50 to 0.52) at 3 months, and 0.27 (-0.40 to 0.95) at 6 months; significant differences were found at 2 weeks and 2 months. The WMDs in the 17:00 IOPR were0.87 mmHg (0.40 to 1.33) at 2 weeks, 0.60 (0.00 to 1.20) at 1 month, 0.65 (-0.69 to 1.99) at 2 months, 0.04 (-0.51 to 0.59) at 3 months, and 0.30 (-0.36 to 0.96) at 12 months, only the first of which was statistically significant. Travoprost was associated with a significantly greater frequency of hyperemia than latanoprost, with an RR of 1.72 (1.33 to 2.23). Rates of serious ocular adverse events did not differ significantly between travoprost and latanoprost, with an RR of 0.22 (0.03 to 1.76) for cystoid macular edema and 2.29 (0.90 to 5.83) for cataract.
Conclusions Although a significant greater efficacy in the diurnal mean or 17:00 IOP reduction of travoprost than latanoprost was found at 2 weeks. Travoprost and latanoprost was comparable in their ability to reduce IOP. Both agents were well tolerated.
打印本文 打印本文 关闭窗口 关闭窗口